title: Feasibility assessment of in vitro chemoresponse assay on stereotactic biopsies of glioblastoma multiforms: a step towards personalized medicine.
abstract: OBJECTIVE
  P In vitro chemosensitivity and resistance assays (CSRAs) are a promising tool for personalized treatment of glioblastoma multiform (GBM). These assays require a minimum of 1 to 2 g of tumor specimen for testing, but this amount is not always accessible. We aimed to assess the feasibility and validity of utilizing stereotactic biopsies of GBM in CSRAs.
  
  
  METHODS
  Single cell suspension was prepared from 1 g weight explants of the established xenograft tumor of GBM. Also, primary culture was carried out on 35 mg weight specimens, as a surrogate for stereotactic biopsies. Then, chemoresponse profile of cells obtained by direct cell disaggregation and primary culture was determined using temozolomide and carmustine by clonogenic assay.
  
  
  RESULTS
  There was no statistically significant difference in the cytotoxicity of temozolomide and carmustine between cells obtained from both methods.
  
  
  CONCLUSIONS
  This work supports the feasibility of using stereotactic biopsies of GBM in CSRAs.
authors.affiliation: Health Management Department, Quality Assurance Deputy, Razi Vaccine & Serum Research Institute, Karaj, Iran.
authors.forename: Fariba
authors.initials: F
authors.lastname: Sadeghi Fazel
authors.affiliation: Cancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mahnaz
authors.initials: M
authors.lastname: Haddadi
authors.affiliation: Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Alireza
authors.initials: A
authors.lastname: Khoshnevisan
authors.affiliation: Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Samad
authors.initials: S
authors.lastname: Muhammadnejad
authors.affiliation: Cancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Ahad
authors.initials: A
authors.lastname: Muhammadnejad
authors.affiliation: Anatomy Department, School of Medicine, Tarbiat Modares University, Tehran, Iran.
authors.forename: Zohreh
authors.initials: Z
authors.lastname: Mazaheri
authors.affiliation: Omid Institute for Advance Biomodels, Incubation Center for Medical Devices, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Motahareh
authors.initials: M
authors.lastname: Arjomandnejad
authors.affiliation: Cancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Reza
authors.initials: R
authors.lastname: Shirkoohi
authors.affiliation: Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mohammad-Ali
authors.initials: MA
authors.lastname: Oghabian
authors.affiliation: Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Narjes
authors.initials: N
authors.lastname: Sherkat-Khameneh
authors.affiliation: Cancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Saeid
authors.initials: S
authors.lastname: Amanpour
authors.affiliation: Virology Department, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Monireh
authors.initials: M
authors.lastname: Kazemimanesh
keywords: Glioblastomamultiform; In vitro chemosensitivity and resistance assay; Personalized medicine; Primary explant technique; Stereotactic biopsy